TMDX TransMedics Group, Inc.

85.25USD-9.33%Mkt Cap: 2.96B USDP/E: 23.23

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides…

Insiders, last 90 days1 buy
Institutional holders20 on file

Key Statistics

Company
Market Cap2.96B USD
Enterprise Value3.64B USD
Revenue (TTM)727.65M USD
Gross Profit362.81M USD
Net Income (TTM)190.29M USD
Revenue/Share21.11 USD
Last Price85.25 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees898
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)23.23
P/E (Forward)34.31
PEG0.96
EV/EBITDA27.98
EV/Revenue5.00
P/S4.07
P/B5.38
EPS (TTM)3.67 USD
EPS (Forward)2.49 USD
52W Range
60.1026% of range156.00
52W High156.00 USD
52W Low60.10 USD
Profitability
Gross Margin59.92%
Oper. Margin11.88%
EBITDA Margin17.88%
Profit Margin31.43%
ROE40.22%
ROA17.81%
ROIC21.54%
ROCE11.09%
Growth
Revenue Growth41.10%
Earnings Growth-29.80%
Cash Flow & Leverage
Operating CF192.84M USD
CapEx (TTM)59.25M USD
FCF Margin3.87%
FCF Yield0.95%
Net Debt373.94M USD
Net Debt/EBITDA2.87
Net Debt/FCF13.28
Balance Sheet
Debt/Equity1.10
Current Ratio4.53
Quick Ratio3.98
Book Value/Sh15.86 USD
Cash/Share14.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)105.45 USD
Upside (mean)+23.7%
Target Range80.00 USD – 125.00 USD
80.00+23.7% to mean125.00
# Analysts11
Ownership
Shares Out.34.73M
Float33.62M
Insiders3.70%
Institutions106.45%
Short Interest
Short Ratio10.1d
Short % Float39.77%
Short % Out.25.57%
Shares Short8.88M
Short (prev mo.)8.55M
Technical
SMA 5080.64 (+5.7%)
SMA 20091.03 (-6.3%)
Beta2.10
S&P 52W Chg12.00%
Avg Vol (30d)1.14M
Avg Vol (10d)1.47M
Technical Indicators
RSI (14)52.0
MACD4.4105
MACD Signal3.3393
MACD Hist.+1.0712
BB Upper105.75 USD
BB Middle81.31 USD
BB Lower56.88 USD
BB Width60.11%
ATR (14)5.290 USD
Vol Ratio (20d)1.27x

About TransMedics Group (NASDAQ: TMDX)

›

TransMedics Group (NASDAQ: TMDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 898 employees.

The shares were at 85.25 USD on 20 November 2026, down 31.8% over 52 weeks. Its 52-week range is 60.10 USD to 156.00 USD: the price is 45.4% below the high and 41.8% above the low.

At a market capitalisation of 2.96B USD, it trades at 23.2 times trailing earnings and 34.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, so TMDX is valued in line with them.

TransMedics Group reports return on equity of 40.2%, an operating margin of 11.9% and revenue up 41.1% year over year.

Its debt exceeds its cash by 373.94M USD, a debt-to-equity ratio of 1.10. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 105.45 USD is 23.7% above the current price. The next earnings report is expected on 1 March 2027.